Royalty Pharma plc Net Income

The latest net income for RPRX is $820M as of June 2026. That compares with $1B in the prior-year period — down 20.1% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Royalty Pharma plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, RPRX's net income moved from $1B to $820M — a 20.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Royalty Pharma plc's operating scale or balance-sheet position.

Against Healthcare companies, RPRX currently prints $820M for net income, while the sector average sits near $16B. That is roughly 94.9% below the sector mean. Large gaps often invite a closer look at Royalty Pharma plc's growth, margins, and balance sheet.

A net income figure of $820M for RPRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting RPRX's net income ($820M), review year-over-year change from $1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.